Literature DB >> 22096027

A noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia.

Padmaja Gade1, Annique Wilson-Weekes2,3, Rajasubramaniam Shanmugam2,3, Hamid Sayar2, Attaya Suvannasankha2,3, Chirayu Goswami4, Lang Li4, Sushil Gupta2, Angelo A Cardoso2, Tareq Al Baghdadi2, Katie J Sargent5, Larry D Cripe2, Dhananjaya V Kalvakolanu1, H Scott Boswell2,3.   

Abstract

PURPOSE: Death-associated protein kinase 1 (DAPK1), a tumor suppressor, is a rate-limiting effector in an endoplasmic reticulum (ER) stress-dependent apoptotic pathway. Its expression is epigenetically suppressed in several tumors. A mechanistic basis for epigenetic/transcriptional repression of DAPK1 was investigated in certain forms of acute myeloid leukemia (AML) with poor prognosis, which lacked ER stress-induced apoptosis. EXPERIMENTAL
DESIGN: Heterogeneous primary AMLs were screened to identify a subgroup with Flt3ITD in which repression of DAPK1, among NF-κB-and c-Jun-responsive genes, was studied. RNA interference knockdown studies were carried out in an Flt3ITD(+) cell line, MV-4-11, to establish genetic epistasis in the pathway Flt3ITD-TAK1-DAPK1 repression, and chromatin immunoprecipitations were carried out to identify proximate effector proteins, including TAK1-activated p52NF-κB, at the DAPK1 locus.
RESULTS: AMLs characterized by normal karyotype with Flt3ITD were found to have 10- to 100-fold lower DAPK1 transcripts normalized to the expression of c-Jun, a transcriptional activator of DAPK1, as compared with a heterogeneous cytogenetic category. In addition, Meis1, a c-Jun-responsive adverse AML prognostic gene signature was measured as control. These Flt3ITD(+) AMLs overexpress relB, a transcriptional repressor, which forms active heterodimers with p52NF-κB. Chromatin immunoprecipitation assays identified p52NF-κB binding to the DAPK1 promoter together with histone deacetylase 2 (HDAC2) and HDAC6 in the Flt3ITD(+) human AML cell line MV-4-11. Knockdown of p52NF-κB or its upstream regulator, NF-κB-inducing kinase (NIK), de-repressed DAPK1. DAPK1-repressed primary Flt3ITD(+) AMLs had selective nuclear activation of p52NF-κB.
CONCLUSIONS: Flt3ITD promotes a noncanonical pathway via TAK1 and p52NF-κB to suppress DAPK1 in association with HDACs, which explains DAPK1 repression in Flt3ITD(+) AML. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22096027      PMCID: PMC3918433          DOI: 10.1158/1078-0432.CCR-10-3022

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress.

Authors:  Jun Hayakawa; Shalu Mittal; Yipeng Wang; Kemal S Korkmaz; Eileen Adamson; Christopher English; Masahide Ohmichi; Masahide Omichi; Michael McClelland; Dan Mercola
Journal:  Mol Cell       Date:  2004-11-19       Impact factor: 17.970

3.  The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway.

Authors:  J Ninomiya-Tsuji; K Kishimoto; A Hiyama; J Inoue; Z Cao; K Matsumoto
Journal:  Nature       Date:  1999-03-18       Impact factor: 49.962

4.  IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition.

Authors:  M Germana Sanna; Jean da Silva Correia; Odile Ducrey; Jongdae Lee; Ken Nomoto; Nicolas Schrantz; Quinn L Deveraux; Richard J Ulevitch
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

5.  dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53.

Authors:  Alain Martoriati; Gilles Doumont; Myriam Alcalay; Eric Bellefroid; Pier Giuseppe Pelicci; Jean-Christophe Marine
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

6.  Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts.

Authors:  Patricia Hess; German Pihan; Charles L Sawyers; Richard A Flavell; Roger J Davis
Journal:  Nat Genet       Date:  2002-08-05       Impact factor: 38.330

7.  Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors:  Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

8.  Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis.

Authors:  B E Wilson; E Mochon; L M Boxer
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

Authors:  Rui Zheng; Mark Levis; Obdulio Piloto; Patrick Brown; Brenda R Baldwin; Norbert C Gorin; Miloslav Beran; Zhenping Zhu; Dale Ludwig; Dan Hicklin; Larry Witte; Yiwen Li; Donald Small
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

10.  Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.

Authors:  Jennifer J Westendorf; S Kaleem Zaidi; Jonathan E Cascino; Rachel Kahler; André J van Wijnen; Jane B Lian; Minoru Yoshida; Gary S Stein; Xiaodong Li
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

View more
  20 in total

Review 1.  NF-κB pathways in hematological malignancies.

Authors:  Chiara Gasparini; Claudio Celeghini; Lorenzo Monasta; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2014-01-14       Impact factor: 9.261

2.  Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.

Authors:  Tzu-Pei Chang; Vladimir Poltoratsky; Ivana Vancurova
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

3.  Death-associated Protein Kinase-1 Expression and Autophagy in Chronic Lymphocytic Leukemia Are Dependent on Activating Transcription Factor-6 and CCAAT/Enhancer-binding Protein-β.

Authors:  Padmaja Gade; Amy S Kimball; Angela C DiNardo; Priyamvada Gangwal; Douglas D Ross; H Scott Boswell; Susan K Keay; Dhananjaya V Kalvakolanu
Journal:  J Biol Chem       Date:  2016-09-02       Impact factor: 5.157

Review 4.  Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention.

Authors:  Srimanta Patra; Prakash P Praharaj; Daniel J Klionsky; Sujit K Bhutia
Journal:  Drug Discov Today       Date:  2021-08-13       Impact factor: 7.851

5.  Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency.

Authors:  Karin Chen; Emily M Coonrod; Attila Kumánovics; Zechariah F Franks; Jacob D Durtschi; Rebecca L Margraf; Wilfred Wu; Nahla M Heikal; Nancy H Augustine; Perry G Ridge; Harry R Hill; Lynn B Jorde; Andrew S Weyrich; Guy A Zimmerman; Adi V Gundlapalli; John F Bohnsack; Karl V Voelkerding
Journal:  Am J Hum Genet       Date:  2013-10-17       Impact factor: 11.025

Review 6.  Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.

Authors:  Jianbiao Zhou; Ying Qing Ching; Wee-Joo Chng
Journal:  Oncotarget       Date:  2015-03-20

Review 7.  Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review).

Authors:  Sara Steinmann; Kristina Scheibe; Katharina Erlenbach-Wuensch; Clemens Neufert; Regine Schneider-Stock
Journal:  Int J Oncol       Date:  2015-05-11       Impact factor: 5.650

8.  The DAXX co-repressor is directly recruited to active regulatory elements genome-wide to regulate autophagy programs in a model of human prostate cancer.

Authors:  Lorena A Puto; Christopher Benner; Tony Hunter
Journal:  Oncoscience       Date:  2015-04-17

Review 9.  The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis.

Authors:  Danjie Jiang; Qingxiao Hong; Yusheng Shen; Yan Xu; Huangkai Zhu; Yirun Li; Chunjing Xu; Guifang Ouyang; Shiwei Duan
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

Review 10.  Therapeutic Vulnerabilities of Transcription Factors in AML.

Authors:  Irum Khan; Elizabeth E Eklund; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2020-11-06       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.